Medical - Devices
Compare Stocks
2 / 10Stock Comparison
VANI vs TNDM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
VANI vs TNDM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $72M | $1.27B |
| Revenue (TTM) | $0.00 | $1.03B |
| Net Income (TTM) | $-26M | $-95M |
| Gross Margin | — | 54.9% |
| Operating Margin | — | -7.9% |
| Total Debt | $19M | $444M |
| Cash & Equiv. | $18M | $91M |
VANI vs TNDM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Vivani Medical, Inc. (VANI) | 100 | 42.2 | -57.8% |
| Tandem Diabetes Car… (TNDM) | 100 | 22.2 | -77.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VANI vs TNDM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VANI has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 1.38
- EPS growth 14.0%
- Lower volatility, beta 1.38, current ratio 3.41x
TNDM is the clearest fit if your priority is long-term compounding.
- -75.4% 10Y total return vs VANI's -98.8%
- 7.9% revenue growth vs VANI's -11.5%
- -10.0% ROA vs VANI's -103.9%, ROIC -10.0% vs -94.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.9% revenue growth vs VANI's -11.5% | |
| Stability / Safety | Beta 1.38 vs TNDM's 1.45, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +18.6% vs TNDM's -17.0% | |
| Efficiency (ROA) | -10.0% ROA vs VANI's -103.9%, ROIC -10.0% vs -94.0% |
VANI vs TNDM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VANI vs TNDM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
TNDM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TNDM and VANI operate at a comparable scale, with $1.0B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.0B |
| EBITDAEarnings before interest/tax | -$27M | -$68M |
| Net IncomeAfter-tax profit | -$26M | -$95M |
| Free Cash FlowCash after capex | -$25M | -$4M |
| Gross MarginGross profit ÷ Revenue | — | +54.9% |
| Operating MarginEBIT ÷ Revenue | — | -7.9% |
| Net MarginNet income ÷ Revenue | — | -9.2% |
| FCF MarginFCF ÷ Revenue | — | -0.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +5.5% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +84.8% |
Valuation Metrics
Evenly matched — VANI and TNDM each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $72M | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $73M | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -2.81x | -6.08x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.25x |
| Price / BookPrice ÷ Book value/share | 3.78x | 8.01x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
TNDM leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TNDM delivers a -68.3% return on equity — every $100 of shareholder capital generates $-68 in annual profit, vs $-20 for VANI. VANI carries lower financial leverage with a 1.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNDM's 2.86x. On the Piotroski fundamental quality scale (0–9), TNDM scores 3/9 vs VANI's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -19.9% | -68.3% |
| ROA (TTM)Return on assets | -103.9% | -10.0% |
| ROICReturn on invested capital | -94.0% | -10.0% |
| ROCEReturn on capital employed | -65.2% | -11.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 1.10x | 2.86x |
| Net DebtTotal debt minus cash | $961,000 | $354M |
| Cash & Equiv.Liquid assets | $18M | $91M |
| Total DebtShort + long-term debt | $19M | $444M |
| Interest CoverageEBIT ÷ Interest expense | — | -15.99x |
Total Returns (Dividends Reinvested)
VANI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TNDM five years ago would be worth $2,195 today (with dividends reinvested), compared to $727 for VANI. Over the past 12 months, VANI leads with a +18.6% total return vs TNDM's -17.0%. The 3-year compound annual growth rate (CAGR) favors VANI at -3.3% vs TNDM's -18.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -4.7% | -14.3% |
| 1-Year ReturnPast 12 months | +18.6% | -17.0% |
| 3-Year ReturnCumulative with dividends | -9.7% | -44.8% |
| 5-Year ReturnCumulative with dividends | -92.7% | -78.0% |
| 10-Year ReturnCumulative with dividends | -98.8% | -75.4% |
| CAGR (3Y)Annualised 3-year return | -3.3% | -18.0% |
Risk & Volatility
VANI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
VANI is the less volatile stock with a 1.38 beta — it tends to amplify market swings less than TNDM's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 1.45x |
| 52-Week HighHighest price in past year | $1.92 | $29.65 |
| 52-Week LowLowest price in past year | $0.92 | $9.98 |
| % of 52W HighCurrent price vs 52-week peak | +63.0% | +62.3% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 235K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates VANI as "Buy" and TNDM as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $31.62 |
| # AnalystsCovering analysts | 2 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TNDM leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VANI leads in 2 (Total Returns, Risk & Volatility). 1 tied.
VANI vs TNDM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VANI or TNDM a better buy right now?
Analysts rate Vivani Medical, Inc.
(VANI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VANI or TNDM?
Over the past 5 years, Tandem Diabetes Care, Inc.
(TNDM) delivered a total return of -78. 0%, compared to -92. 7% for Vivani Medical, Inc. (VANI). Over 10 years, the gap is even starker: TNDM returned -75. 4% versus VANI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VANI or TNDM?
By beta (market sensitivity over 5 years), Vivani Medical, Inc.
(VANI) is the lower-risk stock at 1. 38β versus Tandem Diabetes Care, Inc. 's 1. 45β — meaning TNDM is approximately 5% more volatile than VANI relative to the S&P 500. On balance sheet safety, Vivani Medical, Inc. (VANI) carries a lower debt/equity ratio of 110% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VANI or TNDM?
On earnings-per-share growth, the picture is similar: Vivani Medical, Inc.
grew EPS 14. 0% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VANI or TNDM?
Vivani Medical, Inc.
(VANI) is the more profitable company, earning 0. 0% net margin versus -20. 2% for Tandem Diabetes Care, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VANI leads at 0. 0% versus -7. 7% for TNDM. At the gross margin level — before operating expenses — TNDM leads at 52. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VANI or TNDM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VANI or TNDM better for a retirement portfolio?
For long-horizon retirement investors, Vivani Medical, Inc.
(VANI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (VANI: -98. 8%, TNDM: -75. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VANI and TNDM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.